Evidence map›Paper›PMID 40144041›Full record

ArticleTherapeutic advances in neurological disorders2025

Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis.

Yufan Zhou, Qian Zhou, Yaoxian Yue, Sushan Luo, Jie Song, Chong Yan, Dingxian He, Jialong Zhang, Wenhua Zhu, Chongbo Zhao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in neurological disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yufan ZhouDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0009-0004-5029-290X
Qian ZhouDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Yaoxian YueDepartment of Neurology, Qilu Hospital (Qingdao), Shandong University, Qingdao, China.
Sushan LuoDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-9033-7568
Jie SongDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0009-0003-5298-3993
Chong YanDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Dingxian HeDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0009-0005-9955-7179
Jialong ZhangDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Wenhua ZhuDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Chongbo ZhaoDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-9481-1418
Huan YangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-8690-2544
Qinzhou WangDepartment of Neurology, Qilu Hospital, Shandong University, 107 Wenhua Xilu, Jinan 250012, China.ORCID https://orcid.org/0000-0001-5652-3431
Jianying XiDepartment of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai 200040, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The efficacy of efgartigimod in treating myasthenia gravis (MG) patients with muscle-specific kinase (MuSK) antibodies has not been demonstrated in the clinical trial, existing case reports, or observational studies. Objectives: To evaluate the efficacy and safety of efgartigimod combined with immunotherapies such as tacrolimus or B-cell depleting agents, as maintenance treatment for MuSK-MG patients. Design: This retrospective study included 14 MuSK-MG patients treated with efgartigimod at three tertiary hospitals from 2023 to 2024. Methods: Data on the activities of daily living (ADL) scores, Quantitative Myasthenia Gravis scores, and the time reaching minimal symptom expression (MSE) were collected. The combined use of steroids, immunosuppressants, and rescue therapies, as well as the adverse event incidence, were also recorded. Results: The mean age at first efgartigimod treatment was 55 ± 18 years old with a median follow-up time of 28 weeks. From baseline to week 4, MG-ADL scores decreased significantly from 10.1 ± 4.0 to 2.2 ± 3.1 ( Conclusion: A single-cycle efgartigimod as an induction therapy, combined with immunotherapies such as tacrolimus or B cell depleting agents, as maintenance treatment, could benefit MuSK-MG patients.

Indexed as

efgartigimodmuscle-specific kinasemyasthenia gravisrituximabtacrolimus

Identifiers

PMID40144041
PMCPMC11938440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.